小剂量阿司匹林和噻氯匹定合用在缺血性脑血管病中抗聚效果的观察

The Efficacy of Low Dose Aspirin and Ticlopidine Combination on Antiplatelet Aggregation in Ischemic Cerebral Vascular Disease

目的 :观察阿司匹林 (ASA)和噻氯匹定 (TIC)合用对ICVD患者血小板聚集功能的影响。方法 :用花生四烯酸 (AA)、二磷酸腺苷 (ADP)、肾上腺素 (EPN)和胶原 (COL)做诱导剂检测ICVD患者合用ASA +TIC组与单用TIC或ASA组的血小板聚集率。结果 :合用组对EPN、COL、AA诱导聚集的抑制与TIC组比较差异有显著性 ,对ADP诱导聚集的抑制与ASA组比较差异有显著性 ,P均 <0 0 1。结论 :两者合用后的抗聚效果有相加及协同作用。对需加强抗聚的患者 ,在监测下小剂量的ASA和TIC合用有较好的价 /效比 ,可做为高危ICVD二级预防的一种选择。

Aim:To observe the anti-platelet efficacy of the combined therapy of aspirin (ASA) and ticlopidine (TIC) in patients with ischemic cerebral vascular disease (ICVD).Methods:Platelet aggregation tests induced by arachidonic acid (AA), adenosine diphosphate (ADP), epinephrine (EPN), and collagen (COL) using Born's method were determined in patients with ICVD treated with ASA plus TIC groups, ASA alone groups and TIC alone group.Results:The decrease of the maxiumu aggregation rate (MAR) induced by EPN, COL, AA in ASA plus TIC groups were significantly different with TIC alone group, the decrease of MAR induced by ADP in combined groups were significantly different with ASA alone groups, both P<0.01.Conclusion:There is an adding and enhancing anti-platelet efficacy of the combined therapy of low dose ASA and TIC. For patients who need stronger anti-platelet therapy, the combined therapy has rather better cost/efficacy ratio under monitoring, and it might be a choice of secondary prevention of ICVD.